Cardiovascular Risks in Androgen Deprivation Therapy
Recent studies have confirmed that cardiovascular disease is the leading cause of non-cancer-related death among prostate cancer patients, with ADT exacerbating preexisting CV conditions and contributing to new-onset cardiometabolic complications.1
Prostate cancer is the second most common cancer in men worldwide, and ADT remains a cornerstone of treatment. Emerging evidence shows that Androgen Deprivation Therapy (ADT) may be associated with increased cardiovascular risk, including myocardial infarction, stroke, arrhythmias, and cardiovascular-related mortality.
HeartBEATS from Lifelong Learning™
HeartBEATS from Lifelong Learning™ are bite sized, on demand activities that deliver practical, guideline-based education through podcasts, vodcasts, and other mobile friendly formats. Explore the series and elevate your practice.
Prostate Cancer, Androgen Deprivation Therapy, and Cardiovascular Risk
Learn to recognize, assess, and address the cardiovascular risks associated with androgen deprivation therapy in patients with prostate cancer.
CV Risks in ADT Infographic
Androgen Deprivation Therapy (ADT): Mechanisms and associated cardiovascular side effects
Guidelines and Articles
- Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer
- Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis
- Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial
- Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
- Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System
- A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer